Savara Inc SVRA
Institutional shares held
158 Million
67.6K
calls
29.4K
puts
Total value of holdings
$464M
$198K
calls
$86K
puts
Market Cap
$335M
114,043,000
Shares Out.
Institutional ownership
138.51%
# of Institutions
129
We take great care to ensure that the data presented and summarized in this overview for Savara Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SVRA
View all-
Nea Management Company, LLC Timonium, MD24.5MShares$71.9 Million7.93% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA14.6MShares$42.8 Million11.08% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$36.3 Million6.8% of portfolio
-
Wellington Management Group LLP Boston, MA8.62MShares$25.4 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.16MShares$24 Million1.86% of portfolio
-
Vestal Point Capital, LP New York, NY8.09MShares$23.8 Million2.6% of portfolio
-
Black Rock Inc. New York, NY8.03MShares$23.6 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.94MShares$23.4 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.75MShares$19.9 Million0.05% of portfolio
-
Jennison Associates LLC6.73MShares$19.8 Million0.02% of portfolio
Latest Institutional Activity in SVRA
Top Purchases
Top Sells
About SVRA
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Insider Transactions at SVRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 19
2024
|
Joseph S Mc Cracken |
BUY
Open market or private purchase
|
Direct |
20,000
+8.66%
|
$40,000
$2.95 P/Share
|
|
Nov 18
2024
|
David A Ramsay |
BUY
Open market or private purchase
|
Direct |
100,000
+4.13%
|
$200,000
$2.88 P/Share
|
|
Nov 10
2024
|
Raymond Dennis Pratt Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
49,950
-16.11%
|
$149,850
$3.97 P/Share
|
|
Oct 21
2024
|
Anne Erickson Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
381
-0.11%
|
$1,143
$3.57 P/Share
|
|
Sep 25
2024
|
Braden C. Parker Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
85,000
+50.0%
|
-
|
|
Jul 21
2024
|
Anne Erickson Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
381
-0.11%
|
$1,524
$4.47 P/Share
|
|
Apr 21
2024
|
Anne Erickson Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
381
-0.11%
|
$1,524
$4.81 P/Share
|
|
Dec 28
2023
|
David L Lowrance CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
10,000
-2.84%
|
$40,000
$4.71 P/Share
|
|
Dec 28
2023
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Bona fide gift
|
Direct |
19,000
-1.46%
|
-
|
|
Dec 28
2023
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
84,000
-6.06%
|
$336,000
$4.71 P/Share
|
|
Dec 28
2023
|
Nevan C Elam Director |
SELL
Open market or private sale
|
Direct |
93,843
-80.66%
|
$375,372
$4.71 P/Share
|
|
Dec 28
2023
|
Nevan C Elam Director |
BUY
Exercise of conversion of derivative security
|
Direct |
53,758
+13.94%
|
$53,758
$1.21 P/Share
|
|
Dec 15
2023
|
David L Lowrance CHIEF FINANCIAL OFFICER |
SELL
Bona fide gift
|
Direct |
20,000
-5.37%
|
-
|
|
Dec 14
2023
|
Raymond Dennis Pratt Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+32.61%
|
-
|
|
Dec 14
2023
|
Ricky Sun |
BUY
Grant, award, or other acquisition
|
Direct |
22,500
+50.0%
|
-
|
|
Dec 14
2023
|
David L Lowrance CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+30.06%
|
-
|
|
Dec 14
2023
|
David L Lowrance CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
30,438
-12.54%
|
$121,752
$4.45 P/Share
|
|
Dec 14
2023
|
Robert Matthew Lutz Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
160,000
+34.78%
|
-
|
|
Dec 14
2023
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
450,000
+24.5%
|
-
|
|
Dec 14
2023
|
Matthew Pauls CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
109,680
-10.48%
|
$438,720
$4.45 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.34M
Shares
From
15
Insiders
| Grant, award, or other acquisition | 1.14M shares |
|---|---|
| Open market or private purchase | 120K shares |
| Exercise of conversion of derivative security | 75.4K shares |
Sell / Disposition
418K
Shares
From
9
Insiders
| Open market or private sale | 188K shares |
|---|---|
| Payment of exercise price or tax liability | 191K shares |
| Bona fide gift | 39K shares |